Loading clinical trials...
Loading clinical trials...
As sitaxsentan is the agent most highly selective for ETA (Endothelin Type A (receptor)), and does not significantly impact sildenafil pharmacokinetics the combination of most promise for pulmonary ar...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Pfizer
NCT07481981 · Pulmonary Arterial Hypertension
NCT07365332 · Pulmonary Arterial Hypertension
NCT07218029 · Pulmonary Arterial Hypertension
NCT06649110 · Healthy Volunteers, Pulmonary Arterial Hypertension
NCT07333183 · Pulmonary Hypertension, Interstitial Lung Disease (ILD), and more
Pfizer Investigational Site
Fountain Valley, California
Pfizer Investigational Site
Cluj-Napoca
Pfizer Investigational Site
Kyiv
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions